Evidence map›Paper›PMID 42196582›Full record

ReviewInternational journal of molecular sciences2026

Federica Randisi, Giulia Modoni, Mattia Riva, Gianpaolo Perletti, Davide Odorico, Emanuela Marras, Marzia Bruna Gariboldi

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Federica RandisiDepartment of Biotechnology and Life Sciences (DBSV), University of Insubria, 21100 Varese, Italy.
Giulia ModoniDepartment of Biotechnology and Life Sciences (DBSV), University of Insubria, 21100 Varese, Italy.ORCID 0009-0005-2726-6655
Mattia RivaDepartment of Biotechnology and Life Sciences (DBSV), University of Insubria, 21100 Varese, Italy.ORCID 0009-0004-1657-1665
Gianpaolo PerlettiDepartment of Biotechnology and Life Sciences (DBSV), University of Insubria, 21100 Varese, Italy.ORCID 0000-0001-7209-9191
Davide OdoricoDepartment of Biotechnology and Life Sciences (DBSV), University of Insubria, 21100 Varese, Italy.
Emanuela MarrasDepartment of Biotechnology and Life Sciences (DBSV), University of Insubria, 21100 Varese, Italy.ORCID 0000-0002-9363-1201
Marzia Bruna GariboldiDepartment of Biotechnology and Life Sciences (DBSV), University of Insubria, 21100 Varese, Italy.ORCID 0000-0002-5683-0885

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Prostate cancer (PCa) is the second most frequently diagnosed solid malignancy in men and a major cause of cancer-related mortality worldwide. While localized disease is associated with excellent long-term survival, advanced and castration-resistant PCa continues to represent a major therapeutic challenge. Current management ranges from active surveillance for indolent tumors to multimodal systemic approaches for metastatic disease. In this context, natural compounds are attracting increasing interest as adjunctive or novel therapeutic agents. Among these, silymarin, a

Indexed as

Antineoplastic Agents, PhytogenicProstatic NeoplasmsSilybum marianumSilymarinAnimalsApoptosisCell ProliferationHumansMaleSignal TransductionAntineoplastic Agents, PhytogenicSilymarinhuman studiesin vitro studiesin vivo studiesmilk thistleprostate cancersilibininSilybum marianumsilymarin

Identifiers

PMID42196582
PMCPMC13206769

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.